CHALLENGE

• A manufacturer who was traditionally a research organization was making the transition to a become a commercialization company.

​

• The company had limited personnel and economic resources and was looking for a partner to help bring their first commercial product to market.

OUR APPROACH

• D2 evaluated the distribution options and given the unique specialty characteristics of the product and the significant patient support requirements conducted a full RFP process to identify the best approach.

​

• This process resulted in the successful selection both a HUB partner and Specialty Pharmacy delivery model.

​

• D2 then turned its attention to conducting a robust round of payer research — including pricing models and advisory boards — to determine both market access considerations and potential pricing and contracting needs.

OUTCOMES

• With D2’s assistance, the manufacturer selected an exclusive distribution model. This model enabled patient centric support without limiting access to patients with this rare disease.

​

• D2’s managed care team provided full MCO coverage and attained virtually 100% market coverage, including largely consistent application of Prior Authorization requirements among many key payers in the market.